Skip to main content
. 2018 May 29;9(41):26353–26369. doi: 10.18632/oncotarget.25293

Figure 3. LDC526 decreases splenic human CLL numbers in xenografted NSG mice.

Figure 3

(A) Scheme of the experimental set-up. CLL cells of individual patients were i.v. injected into n=3-4 NSG mice per treatment group (carrier control, LDC526 50 mg/kg and 75 mg/kg). One cohort of NSG mice transplanted with cells from n=3 individual CLL patients was analyzed on day 17. Another cohort of NSG mice transplanted with cells from n=3 further CLL patients was analyzed on day 21. (B) Representative flow cytometric analysis (day 21) of splenocytes of human CLL transplanted NSG mice treated with carrier or LDC526, respectively. (C) Quantification of splenic human CLL and splenic human T cells after carrier control and LDC526 treatment, respectively. Each data point represents the mean±SEM of NSG spleen cell numbers per individual CLL patient normalized to the mean cell numbers detected in spleens of corresponding carrier control treated mice (transplanted with the same leukemia). Mean CLL cell numbers were statistically compared in paired analyses. Tables depict the numbers of recipient NSG mice analyzed per data point. * p<0.05; ** p<0.01.